A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

You are here

This is a multicenter, randomized, open-label study of Toca 511 and Toca FC versus standard of care (SOC) in subjects undergoing resection for first or second recurrence (including this recurrence) of glioblastoma or anaplastic astrocytoma. Subjects will be randomized at the time of surgery in a 1:1 ratio to receive either Toca 511 and Toca FC or control; Investigator's choice of either single agent chemotherapy (lomustine or temozolomide) or bevacizumab.

This study aims to compare the overall survival (OS) of subjects treated with Toca 511 combined with Toca FC to subjects treated according to standard of care after tumor resection for recurrence of glioblastoma or anaplastic astrocytoma.

Contact Dr. Rohan Ramakrishna: 212-746-1996

More information about this trial can be found on clinicaltrials.gov